GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part — 62 comments in the full submission. View in context.
1k
c/survodutide·submitted 6 months ago by u/incretin_ivy

[Lab] 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part

Discussionbranch of 16 comments

Short version of the title, which is already short: 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part. Longer version underneath. Since the title puts numbers in the shop window: 98.4% and 98.0%. The honest evidence position, written out so this board does not drift. Phase…

Read the full submission and all 62 comments →

This branch

16 comments, started 6 months ago
u/lina_ndiaye71 points·6 months ago

fibrosis improvement without worsening steatohepatitis is the phrase to learn

replysharereportpermalink
u/deleted_my_history16 points·6 months ago

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

replysharereportpermalink
u/hub_opssite staff6 points·6 months ago

the weight numbers are secondary to what this is being developed for

replysharereportpermalink
u/incretin_ivyOPpharmacology7 points·6 months ago

Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.

replysharereportpermalink
u/cesar_ivaturi6 points·6 months ago

research material is not approved for human use, which is why the clinical record here is thin

replysharereportpermalink
u/kian_ferreira21 points·6 months ago

phase 2 in liver disease is a different evidence question from weight

replysharereportpermalink
u/hana_pereira5 points·6 months ago

the hepatic data is what makes this compound different from the others

replysharereportpermalink
u/incretin_ivyOPpharmacology16 points·6 months ago

phase 2 in liver disease is a different evidence question from weight

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/throwaway_wl20269 points·6 months ago

this board is small because the compound is early

replysharereportpermalink
u/tired_ledger_ftw4 points·6 months ago

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

replysharereportpermalink
u/whois_wanda3 points·6 months ago

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

replysharereportpermalink
u/refund_ledger1 point·6 months ago

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

replysharereportpermalink
u/joaquin_ivaturi21 points·6 months ago·edited

fibrosis improvement without worsening steatohepatitis is the phrase to learn

lina_ndiaye is right that biopsy and imaging endpoints are not interchangeable.

replysharereportpermalink
u/kasper_cabrera31 points·6 months ago

biopsy-confirmed is not the same as imaging-suggested

replysharereportpermalink
u/cato_girard25 points·6 months ago

glucagon agonism and energy expenditure is the mechanistic thread

replysharereportpermalink
u/crosspost_bot_no12 points·6 months ago·edited

glucagon agonism and energy expenditure is the mechanistic thread

Disagreeing with this bit: that number comes from a different programme with a different population.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.